Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study

Schizophrenia Research

Volumn 106, Issue 2-3, 2008, Pages 320-327

  Goff, Donald C ^a,b   Cather, Corinne ^a,b   Gottlieb, Jennifer D ^a,b   Evins, A Eden ^a,b   Walsh, Jared ^a   Raeke, Lisa ^a   Otto, Michael W ^d   Schoenfeld, David ^b,c   Green, Michael F ^e  

^a Freedom Trail Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cognition; d cycloserine; Memory consolidation; Negative symptoms; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CYCLOSERINE; FLUPHENAZINE; HALOPERIDOL; LOXAPINE SUCCINATE; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ALOGIA; ANHEDONIA; ANXIETY DISORDER; ARTICLE; AVOLITION; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; EMOTIONAL DISORDER; FATIGUE; FEMALE; FOOT FRACTURE; HEADACHE; HEARTBURN; HUMAN; LOGICAL MEMORY TEST; MALE; MEMORY CONSOLIDATION; NAUSEA; NEGATIVE SYNDROME; OUTCOME ASSESSMENT; OUTPATIENT CARE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECALL; SCHIZOPHRENIA; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THORAX PAIN; TREATMENT OUTCOME; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; CYCLOSERINE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 56049099989     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.08.012     Document Type: Article

References (42)

1. Andersen J.M., Lindberg V., and Myhrer T. Effects of scopolamine and d-cycloserine on non-spatial reference memory in rats. Behav Brain Res 129 (2002) 211-216
2. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS) (1983), University of Iowa, Iowa City
3. Benedict R.H.B., Schretlen D., Groninger L., and Brandt J. Hopkins verbal learning test- revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol 12 (1998) 43-55
4. Benton A., and Hamsher K. Multilingual Aphasia Examination (Manual Revised) (1978), University of Iowa, Iowa City
5. Boje K.M., Wong G., and Skolnick P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 603 2 (1993) 207-214
6. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., and Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31 1 (2005) 5-19
7. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., and Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 164 10 (2007) 1593-1602
8. Davis M., Ressler K., Rothbaum B.O., and Richardson R. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60 4 (2006) 369-375
9. Duffy S., Labrie V., and Roder J.C. D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning. Neuropsychopharmacology 33 5 (2008) 1004-1018
10. Duncan E.J., Szilagyi S., Schwartz M.P., Bugarski-Kirola D., Kunzova A., Negi S., Stephanides M., Efferen T.R., Angrist B., Peselow E., Corwin J., Gonzenbach S., and Rotrosen J.P. Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr Res 71 2-3 (2004) 239-248
11. Evins A., Amico E., Posever T., Toker R., and Goff D. d-Cycloserine augmentation of risperidone in the deficit syndrome of schizophrenia. Schizophr Res 56 (2002) 19-23
12. Flood J., Morley J., and Lanthorn T. Effect on memory processing by d-cycloserine, an agonist of the NMDA/glycine receptor. Eur J Pharmacol 221 (1992) 249-254
13. Goff D.C., and Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158 (2001) 1367-1377
14. Goff D.C., Tsai G., Manoach D.S., and Coyle J.T. Dose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152 (1995) 1213-1215
15. Goff D., Henderson D., Evins A., and Amico E. A placebo-controlled crossover trial of d-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry 45 (1999) 512-514
16. Goff D., Tsai G., Levitt J., Amico E., Manoach D., Schoenfeld D., Hayden D., McCarley R., and Coyle J. A placebo-controlled trial of d-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry 56 (1999) 21-27
17. Goff D.C., Hennen J., Tsai G., Evins A.E., Yurgelun-Todd D., and Renshaw P. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51 (2002) 493-497
18. Goff D.C., Herz L., Posever T., Shih V., Tsai G., Henderson D.C., Freudenreich O., Evins A.E., Yovel I., Zhang H., and Schoenfeld D. A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 179 1 (2005) 144-150
19. Hanngren H., Hansson E., and Ullberg S. An autoradiographic study of the distribution of tritium-labeled cycloserine in mice. Antibiot Chemother 12 (1961) 46-54
20. Heaton R. Wisconsin Card Sorting Test Manual (1990), Psychological Assessment Resources, Inc., Odessa, FL
21. Heresco-Levy U., Javitt D., Ermilov M., Mordel C., Silipo G., and Lichenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry 56 (1999) 29-36
22. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., Shiekh M., and Otto M.W. Augmentation of exposure therapy with d-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63 3 (2006) 298-304
23. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
24. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B.J., and Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51 (1994) 199-214
25. Levine J., and Schooler N. SAFETEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22 (1986) 343-346
26. Manoach D.S., Cain M.S., Vangel M.G., Khurana A., Goff D.C., and Stickgold R. A failure of sleep-dependent procedural learning in chronic, medicated schizophrenia. Biol Psychiatry 56 12 (2004) 951-956
27. Matsuoka N., and Aigner T.G. d-cycloserine, a partial agonist at the glycine site coupled to N-methyl-d-aspartate receptors, improves visual recognition memory in rhesus monkeys. J Pharmacol Exp Ther 278 (1996) 891-897
28. Millan M.J. N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology (Berl) 179 1 (2005) 30-53
29. Nong Y., Huang Y.Q., Ju W., Kalia L.V., Ahmadian G., Wang Y.T., and Salter M.W. Glycine binding primes NMDA receptor internalization. Nature 422 6929 (2003) 302-307
30. Parnas A.S., Weber M., and Richardson R. Effects of multiple exposures to d-cycloserine on extinction of conditioned fear in rats. Neurobiol Learn Mem 83 3 (2005) 224-231
31. Quartermain D., Mower J., Rafferty M.F., Herting R.L., and Lanthorn T.H. Acute but not chronic activation of the NMDA-coupled glycine receptor with d-cycloserine facilitates learning and retention. Eur J Pharmacol 257 (1994) 7-12
32. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., Hodges L., and Davis M. Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61 11 (2004) 1136-1144
33. Santini E., Muller R.U., and Quirk G.J. Consolidation of extinction learning involves transfer from NMDA-independent to NMDA-dependent memory. J Neurosci 21 22 (2001) 9009-9017
34. Schneider J.S., Tinker J.P., Van Velson M., and Giardiniere M. Effects of the partial glycine agonist d-cycloserine on cognitive functioning in chronic low dose MPTP-treated monkeys. Brain Res 860 (2000) 190-194
35. Sheinin A., Shavit S., and Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist d-cycloserine. Neuropharmacology 41 2 (2001) 151-158
36. Spreen O., and Strauss E. A Compendium of Neuropsychological Tests (1991), Oxford University Press, New York
37. Stromme J.T., and Myhrer T. Impaired visual memory in rats reared in isolation is reversed by d-cycloserine in the adult rat. Eur J Pharmacol 15 (2002) 73-77
38. Tsai G., Yang P., Chung L.-C., Lange N., and Coyle J. d-Serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 (1998) 1081-1089
39. Tuominen H.J., Tiihonen J., and Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72 (2005) 225-234
40. van Berckel B., Lipsch C., Timp S., Gispen-de Wied C., Wynne H., van Ree J., and Kahn R. Behavioral and neuroendocrine effects of the partial NMDA agonist d-cycloserine in healthy subjects. Neuropsychopharmacology 16 (1997) 317-324
41. van Berckel B.N.M., Evenblij C.N., van Loon B.J.A.M., Maas M.F., van der Geld M.A.M., Wynne H.J., van Ree J.M., and Kahn R.S. d-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology 21 (1999) 203-210
42. Wechsler D. Wechsler Memory Scale-Third Edition (1997), Psychological Corporation, San Antonio, TX